These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15452942)

  • 21. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
    Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
    Knopp RH; d'Emden M; Smilde JG; Pocock SJ
    Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [How can lipid therapy be improved? Cardiologists insist on dual cholesterol inhibition].
    MMW Fortschr Med; 2005 Nov; 147(45):54. PubMed ID: 16320655
    [No Abstract]   [Full Text] [Related]  

  • 24. Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting.
    Sathyapalan T; Atkin SL; Kilpatrick ES
    Diabet Med; 2008 Aug; 25(8):909-15. PubMed ID: 18959603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lowering of cholesterol. What role is played by the choice of statins?].
    März W
    MMW Fortschr Med; 2004 Sep; 146(35-36):55. PubMed ID: 15540544
    [No Abstract]   [Full Text] [Related]  

  • 27. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
    Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Egido J;
    Am Heart J; 2007 May; 153(5):881-8. PubMed ID: 17452168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
    Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
    Keleş T; Akar Bayram N; Kayhan T; Canbay A; Sahin D; Durmaz T; Ozdemir O; Aydoğdu S; Diker E
    Anadolu Kardiyol Derg; 2008 Dec; 8(6):407-12. PubMed ID: 19103535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Good prevention of type 2 diabetes with lipid-lowering statin therapy. Intervention studies support active treatment of risk patients].
    Nilsson PM; Attvall S; Båvenholm P
    Lakartidningen; 2004 Nov; 101(47):3798, 3801-2, 3804. PubMed ID: 15609534
    [No Abstract]   [Full Text] [Related]  

  • 32. [Type 2 diabetics are high risk patients. Concerning LDL-cholesterol to approach effectively to two sources].
    MMW Fortschr Med; 2005 Nov; 147(44):52-3. PubMed ID: 16302495
    [No Abstract]   [Full Text] [Related]  

  • 33. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
    Hobbs FD
    Int J Cardiol; 2006 Jun; 110(2):137-45. PubMed ID: 16289373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
    Betteridge DJ; Gibson JM
    Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
    Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
    Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Target values are more often attainable. Almost doubly so many patients with values under 100mg/dl].
    MMW Fortschr Med; 2004 Oct; 146(44):57. PubMed ID: 15566254
    [No Abstract]   [Full Text] [Related]  

  • 37. Is C-reactive protein an additional, surrogate end-point for statin treatment?
    Kluft C
    Eur Heart J; 2002 May; 23(10):761-4. PubMed ID: 12009712
    [No Abstract]   [Full Text] [Related]  

  • 38. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program).
    Hobbs FD; Gensini G; Mancini GB; Manolis AJ; Bauer B; Böhler S; Genest J; Feldman R; Harvey P; Jenssen TG; Metcalfe M; da Silva PM;
    Int J Cardiol; 2006 Jun; 110(2):242-50. PubMed ID: 16338012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)].
    März W
    MMW Fortschr Med; 2004 Jul; 146(27-28):53. PubMed ID: 15526673
    [No Abstract]   [Full Text] [Related]  

  • 40. Cholesterol limbo: How low should the bar go. Ratcheting down LDL to extra-low levels with high-dose statins seems to work wonders.
    Harv Health Lett; 2004 May; 29(7):1-2. PubMed ID: 15153394
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.